Zacks Research Has Negative Outlook of IRWD FY2026 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research cut their FY2026 EPS estimates for Ironwood Pharmaceuticals in a research report issued on Tuesday, December 10th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.43 for the year, down from their previous forecast of $0.44. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.08 per share.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, November 12th. Leerink Partners began coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a "market perform" rating and a $5.00 target price on the stock. Finally, Leerink Partnrs upgraded Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.40.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock traded down $0.05 on Friday, hitting $3.51. The stock had a trading volume of 673,495 shares, compared to its average volume of 2,826,715. Ironwood Pharmaceuticals has a one year low of $3.06 and a one year high of $15.70. The business has a 50 day moving average price of $4.03 and a 200 day moving average price of $5.02.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $91.60 million for the quarter, compared to analysts' expectations of $91.22 million. During the same quarter in the previous year, the business earned $0.12 earnings per share. The company's revenue for the quarter was down 19.4% compared to the same quarter last year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. KBC Group NV boosted its holdings in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 3,198 shares during the last quarter. CWM LLC boosted its holdings in Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 2,345 shares during the last quarter. Wolverine Trading LLC acquired a new stake in Ironwood Pharmaceuticals during the 3rd quarter worth about $51,000. Diversified Trust Co purchased a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $52,000. Finally, Legacy Capital Group California Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at about $59,000.

Insider Activity

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.90% of the company's stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.